
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. has demonstrated a strong positive outlook due to encouraging results from multiple clinical studies involving its flagship product, Ampligen (rintatolimod). Notably, the company reported positive data from a Phase 2 study assessing Ampligen for post-COVID conditions in February 2024, building on previous favorable results from an April 2022 Phase 2a study targeting metastatic colorectal cancer. The ongoing success in clinical trials highlights the potential for Ampligen to address significant unmet medical needs, which could drive future revenue growth and positively impact investor sentiment.
Bears say
AIM ImmunoTech Inc reported a net loss of $3.3 million, corresponding to an earnings per share (EPS) of $(1.57), which significantly exceeded analyst estimates of $(0.97) to $(0.98). The company's ongoing financial challenges are compounded by numerous risks, including liquidity concerns, the possibility of product candidates not proving safety and efficacy in clinical trials, and the failure to secure necessary regulatory approvals for commercialization. Additional factors such as competition, changing macroeconomic conditions, and fluctuating investor sentiment towards biotech stocks further contribute to a negative outlook for the company's stock performance.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares